Evaluation of a new "all in one" SARS-CoV-2 antigen-detecting rapid diagnostic test and self-test: Diagnostic performance and usability in child and adult populations.
COVID-19
SARS-CoV-2
antigen testing
children COVID testing
diagnostic testing
nasal sampling
self-test
usability
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
15
04
2022
received:
25
02
2022
accepted:
22
04
2022
pubmed:
28
4
2022
medline:
16
7
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
The control of the COVID-19 epidemics has been one global health priorities for the last 2 years. To that end, more reliable and easy-to-use, regardless of age, diagnostic tests are necessary. Considering that, we evaluated an innovative two-step self-test, the AAZ COVID-VIRO ALL IN®, switching from the classic nasal swab to a nasal sponge. We performed a multicenter study, on 124 adults and children, in a point-of-care setting. Sensitivity, specificity and overall acceptance of the COVID-VIRO ALL IN® self-test compared to reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal samples were of 93.0%, 100%, and 97.5%, respectively. We then performed a multicenter, usability study to evaluate the ease of use of COVID-VIRO ALL IN® on 68 laypersons adults. A vast majority of participants correctly executed and interpreted the test. The usability was then specifically investigated on 40 children and teenagers, comparing COVID-VIRO® first generation to the new COVID-VIRO ALL IN®. They all found COVID-VIRO ALL IN® more comfortable and easier to use. For young children, the new self-test seems safer (less risk of trauma and no liquid exposure), and faster than saliva-based RT-PCR. Moreover, the COVID-VIRO ALL IN® can easily be adapted as a multiplex self-test for other respiratory viruses, opening new perspectives of simultaneous, rapid and massive detection of respiratory infections, especially among vulnerable populations like children and elderly people.
Identifiants
pubmed: 35474460
doi: 10.1002/jmv.27812
pmc: PMC9088384
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4097-4106Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Clin Rev Allergy Immunol. 2013 Dec;45(3):331-79
pubmed: 23575961
J Med Virol. 2022 Sep;94(9):4097-4106
pubmed: 35474460
BMC Public Health. 2021 Dec 4;21(1):2209
pubmed: 34863144
Pediatr Pulmonol. 2022 Jan;57(1):38-42
pubmed: 34644459
J Med Virol. 2021 Dec;93(12):6686-6692
pubmed: 34331707
Yonsei Med J. 2021 Nov;62(11):961-968
pubmed: 34672129
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Investig Med. 2021 Dec;69(8):1399-1403
pubmed: 34348963
Clin Infect Dis. 2021 Jun 15;72(12):2199-2202
pubmed: 32986804
JAMA. 2020 Dec 1;324(21):2153-2154
pubmed: 33185688
Expert Rev Anti Infect Ther. 2016 Oct;14(10):961-8
pubmed: 27560100